Clinical trial · Supplements / medicine · 26 Oct 2026
A phase 3 trial tested a cancer drug after endometrial cancer treatment
Source: EurekAlert
What the research found
NYU Langone reported on 26 October 2026 a phase 3 trial of sacituzumab tirumotecan, a cancer drug, in women already treated for endometrial cancer. 386 women assigned the drug had a 41 percent lower risk of the cancer growing or spreading than 390 women given chemotherapy, the release says. Frequent side effects included low blood counts, mouth soreness, and dry eyes, which the investigators called manageable. Initial data were presented at ESMO and posted in The Lancet. The release does not give an age band. This is a trial of a prescribed cancer medicine, not a supplement someone should start from a headline. Not medical advice.
Evidence level: Clinical trial. This is among the stronger kinds of evidence, but one study rarely settles a question.
More supplements / medicine news
- In mice, the experimental drug KCL-286 reduced DNA breaks and brain inflammation in an Alzheimer's model
- In aged rats, two weeks of the experimental drug cinaciguat cut circulating amyloid-beta about in half and brought LDL down to youthful levels
- In 104 people with a sudden retinal-artery blockage, papaverine use lined up with better functional vision in a retrospective comparison
- A Cell Metabolism letter questions whether a fasting GLP-1 level shows how many gut L-cells a person has
- In FDA reports, caffeine and stimulant supplement use was tied to cardiac arrest about 11 times more often, and 45 percent of those cardiovascular reports were ages 18 to 34